Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy

Bone Marrow Transplantation volume 37, pages 1009–1015 (2006)Cite this article

Abstract

The prognosis for patients with metastatic breast cancer remains poor. Metastatic breast cancer confined to the bones may have a better prognosis, especially hormone receptor-positive disease. We performed a prospective, randomized clinical trial to compare immediate consolidation with high-dose chemotherapy and hematopoietic support versus observation with high-dose consolidation at the time of disease progression in women with metastatic breast cancer and only bone metastases. The patients received chemotherapy with doxorubicin, 5-fluorouracil and methotrexate before randomization. In all, 85 patients were enrolled and 69 were randomized. The median follow-up is 8.1 years from randomization. The median event-free survival (EFS) for the immediate transplant arm is 12 months and for the observation arm is 4.3 months (P<0.0001). The median overall survival for the immediate transplant arm is 2.97 years and for the observation arm 1.81 years, a difference that is not statistically significant. Immediate high-dose chemotherapy and radiation therapy as consolidation offers a clinically and statistically significant improvement in EFS compared with radiation therapy alone following induction chemotherapy for women with metastatic breast cancer confined to the bones.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Chu KC, Tarone RE, Kessler LG, Ries LA, Hankey BF, Miller BA et al. Recent trends in US breast cancer incidence, survival and mortality rates. J Nat Cancer Inst 1996; 88: 1571–1579.

    Article  CAS  PubMed  Google Scholar 

  2. Scheid V, Buzdar AU, Smith TL, Hortobagyi GN . Clinical course of breast cancer patients with osseous metastases treated with combination chemotherapy. Cancer 1986; 58: 2589–2593.

    Article  CAS  PubMed  Google Scholar 

  3. Coleman RE, Rubens RD . The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55: 61–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Dunphy FR, Spitzer G, Buzdar AU, Hortobagyi GN, Horwitz LJ, Yau JC et al. Treatment of estrogen receptor negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 1990; 8: 1207–1216.

    Article  CAS  PubMed  Google Scholar 

  5. Antman KA, Rowlings PA, Vaughan WP, Pelz CJ, Fay JW, Fields KK et al. High dose chemotherapy with autologous hematopoietic stem cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870–1879.

    Article  CAS  PubMed  Google Scholar 

  6. Elias AD, Ibrahim J, Richardson P, Avigan D, Joyce R, Reich E et al. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana Farber/Beth Israel STAMP program. Biol Blood Marrow Transplant 2002; 8: 198–205.

    Article  CAS  PubMed  Google Scholar 

  7. Rowlings PA, Williams SF, Antman KH, Fields KK, Fay JW, Reed E et al. Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA 1999; 282: 1335–1343.

    Article  CAS  PubMed  Google Scholar 

  8. Peters WP, Jones RB, Vredenburgh JJ, Sphall EJ, Hussein A, Elkordy M et al. A large, prospective, randomized trial of high dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Br Cancer Res Treat 1996; 37 (Suppl): 11 (abstract no. 35).

    Google Scholar 

  9. Biron P, Durand M, Delozier T, Roche T, Battista C, Fargeot P et al. High dose Thiotepa (TTP), cyclophosphamide (CPM) and stem cell transplantation after 4 FEC 100 compared with 4 FEC alone allowed a better disease free survival but the same overall survival in first line chemotherapy for metastatic breast cancer. Results of the PEGASE 03 French Protocole. Proc ASCO 2002; 21: 42a (abstract no. 167).

    Google Scholar 

  10. Crump M, Gluck S, Stewart M, Levine M, Pritchard K, Kirkbride P et al. A randomized trial of high-dose chemotherapy (HDC) with autologous peripheral blood stem cell support (ASCT) compared to standard therapy in women with metastatic breast cancer: a National Cancer Institue of Canada (NCIC) Clinical Trials Group study. Proc ASCO 2001; 20: 21a (abstract no. 82).

    Google Scholar 

  11. Pedrazzoli P, Ferrante P, Kulekci A, Schiavo R, DeGiorgi U, Carminati O et al. Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990–1999. Bone Marrow Transplant 2003; 32: 489–494.

    Article  CAS  PubMed  Google Scholar 

  12. Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JW et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplanation for metastatic breast cancer. NEJM 2000; 342: 1069–1076.

    Article  CAS  PubMed  Google Scholar 

  13. Jones RB, Shpall EJ, Shogan J, Olsen GA, Bast RC, Gockerman JP et al. The Duke AFM program: intensive induction chemotherapy for metastatic breast cancer. Cancer 1990; 66: 431–436.

    Article  CAS  PubMed  Google Scholar 

  14. Peters WP, Shpall EJ, Jones RB, Oslen GA, Bast RC, Gockerman JP et al. High dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368–1376.

    Article  CAS  PubMed  Google Scholar 

  15. Vandemark RM, Shpall EJ, Affronti ML . Bone metastases from breast cancer: value of bone windows. J Comput Assist Tomography 1992; 16: 608–614.

    Article  CAS  Google Scholar 

  16. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  17. Petros WP, Broadwater G, Berry D, Jones RB, Vredenburgh JJ, Gilbert CJ et al. Association of high-dose cyclophosphamide, cisplatin and carmustine pharmacokinetics with survival, toxicity and dosing weight in patients with primary breast cancer. Clin Cancer Res 2002; 8: 698–705.

    CAS  PubMed  Google Scholar 

  18. Berry DA, Broadwater G, Klein JP, Antman K, Aisner J, Bitran J et al. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2002; 20: 743–750.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology/Transplantation, Duke University Medical Center, Durham, NC, USA

    J J Vredenburgh, B Madan, D Coniglio, M Ross, J Edwards, L Marks, R Vandemark, C McDonald, M L Affronti & W P Peters

  2. Department of Biostatistics, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, NC, USA

    G Broadwater & D Niedzwiecki

Authors
  1. J J Vredenburgh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Madan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Coniglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Ross
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G Broadwater
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Niedzwiecki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Edwards
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L Marks
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R Vandemark
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C McDonald
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M L Affronti
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. W P Peters
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J J Vredenburgh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vredenburgh, J., Madan, B., Coniglio, D. et al. A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Bone Marrow Transplant 37, 1009–1015 (2006). https://doi.org/10.1038/sj.bmt.1705367

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705367

Keywords

This article is cited by

Search

Advanced search

Quick links